Research programme: viral infection therapies - Quigley PharmaAlternative Names: QR-435; QR-439; QR-441; QR-444; QR-446
Latest Information Update: 16 Jul 2009
At a glance
- Originator Quigley Pharma
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Herpes simplex virus infections; Influenza A virus infections; Severe acute respiratory syndrome
Most Recent Events
- 16 Jul 2009 Preclinical development is ongoing in USA and United Kingdom